Latest news and articles about monthly dosing
Total: 1 articles found
Pfizer’s long‑acting GLP‑1 candidate PF‑08653944 produced a 12.3% placebo‑adjusted mean weight loss at 28 weeks and sustained reductions after switching to monthly dosing, with mainly mild‑to‑moderate gastrointestinal side effects. The company has launched an ambitious phase 3 programme of ten trials and plans to advance full development in 2026, positioning itself to challenge incumbent GLP‑1 therapies if larger trials confirm efficacy and safety.
